Skip to main content
. 2024 Apr 1;24:404. doi: 10.1186/s12885-024-12174-0

Table 2.

Characteristics for immunotherapy cohorts

ZZU cohort (n = 184) SDU cohort (n = 43)
Characteristic CR + PR SD + PD p value CR + PR SD + PD p value
Age (years) 0.874  > 0.999
 < 65 39 (60.94) 75 (62.50) 18 (100) 25 (100)
≥ 65 25 (39.06) 45 (37.50) 0 (0) 0 (0)
Sex 0.308 0.701
 Male 49 (76.56) 83 (69.17) 14 (77.78) 21 (84.00)
 Female 15 (23.44) 37 (30.83) 4 (22.22) 4 (16.00)
Location 0.189 0.624
 Cardia 39 (60.94) 54 (45.00) 6 (33.33) 12 (48.00)
 Body 12 (18.75) 33 (27.50) 5 (27.78) 7 (28.00)
 Antrum 13 (20.31) 31 (25.83) 6 (33.33) 4 (16.00)
 Whole 0 (0.00) 2 (1.67) 1 (5.6) 2 (8.00)
Clinical T stage 0.366 > 0.999
 T3 18 (28.12) 26 (21.67) 0 (0) 0 (0)
 T4 46 (71.88) 94 (78.33) 18 (100) 25 (100)
Clinical N stage 0.457 0.253
 N- 16 (25.00) 24 (20.00) 0 (0) 3 (12.00)
 N+ 48 (75.00) 96 (80.00) 18 (100) 22 (88.00)
CA 72−4 level 0.872 > 0.999
 Normal 21 (32.81) 41 (34.17) 4 (22.22) 5 (20.00)
 Abnormal 43 (67.19) 79 (65.83) 14 (77.78) 20 (80.00)
CA 19−9 level 0.498 0.765
 Normal 16 (25.00) 36 (30.00) 7 (38.89) 11 (44.00)
 Abnormal 48 (75.00) 84 (70.00) 11 (61.11) 14 (56.00)
CEA level 0.640 0.099
 Normal 28 (43.75) 48 (40.00) 15 (83.33) 14 (56.00)
 Abnormal 36 (56.25) 72 (60.00) 3 (16.67) 11 (44.00)
Radiomics score * 1.06 (0.69, 1.35) 1.47 (1.18, 1.87) < 0.001 1.02 (0.03, 1.34) 1.42 (1.00, 1.93) 0.012

Note: Except where indicated, data are number (%) of patients. MSI-H = microsatellite instability-high, MSS = microsatellite stability, CA 72 − 4 = carbohydrate antigen 72 − 4, CA 19 − 9 = carbohydrate antigen 19 − 9, CEA = carcinoembryonic antigen, PFS = Progression-free survival, OS = Overall survival

* Data in parentheses are interquartile range